Altamira Therapeutics Announces Filing of Provisional Patent Application for Oligophore Nanoparticles With Sirna Targeting P65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics宣佈提交具有sirna靶向P65蛋白的寡核納米顆粒的臨時專利申請,用於治療癌症和炎症
Altamira Therapeutics Announces Filing of Provisional Patent Application for Oligophore Nanoparticles With Sirna Targeting P65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics宣佈提交具有sirna靶向P65蛋白的寡核納米顆粒的臨時專利申請,用於治療癌症和炎症
使用瀏覽器的分享功能,分享給你的好友吧